Drug delivery product demand in the US is projected to expand to $251 billion in 2019, with annual growth of 6.1 percent. As the US population expands and ages, domestic manufacturing and consumption of ethical and over-the-counter medicines and nutritional preparations are expected to rise. Commercialization of drug delivery systems and technologies will increase as generic and private label competition intensifies, drug patent protections expire, and pressure grows to hold down medication prices.
This report segments the drug delivery product market by Oral Products, Parenteral Products, and Other Products. These include:
Oral Products: Controlled-release, chewable, nanoparticulate, orally disintegrating, and transmucosal (or buccal) classifications
Parenteral Products: therapeutic monoclonal antibodies, encapsulated systems, infusion systems, and parenteral delivery devices
Other Products: inhalation, transdermal, and implantable therapies
Oral dosage formulations have historically comprised the largest selling group of drug delivery products, and will remain that way through 2019. Total growth will be somewhat hampered by increasing generic competition and reduced pricing flexibility. Parenteral products, including pen injectors and retractable pre-fillable syringes, are expected to post rapid gains as new and existing therapies based monoclonal antibodies contribute to improved effectiveness of treatment for cancer and other long-term disorders.
Therapeutic classes for drug delivery products include the following agents:
Central nervous system
Hormones and related
Central nervous system agents control the largest slice of demand for drug delivery product market by therapeutic class, accounting for more than 25 percent of sales. This trend is expected to continue as treatment of psychological and neurological disorders through continuous dosing, controlled-release medicines becomes increasingly prevalent.
This study also details market share and sales estimates for 30 key participants in the drug delivery products industry. These include Allergan, Animas, AstraZeneca, CareFusion, Evonik, GlaxoSmithKline, Hospira, Johnson & Johnson, Novartis, Pfizer, and Roche.